Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models

Yoko Tamaki, Kunio Maema, Makoto Kakara, Masato Fukae, Ryoko Kinoshita, Yushi Kashihara, Shota Muraki, Takeshi Hirota, Ichiro Ieiri

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

The objective of the present study was to develop a population pharmacodynamic (PPD) model to describe the glycated hemoglobin (HbA1c)-lowering effects of metformin in type 2 diabetes mellitus patients with and without secondary failure and to characterize changes in HbA1c levels in the two subpopulations using a mixture model. Information on patients was collected retrospectively from electronic medical records. In this study, the mixture model was used to characterize the bimodal effects of metformin. A PPD analysis was performed using NONMEM 7.3.0. A physiological indirect response model, based on 829 HbA1c levels of 69 patients, described the time course for the HbA1c-lowering effects of metformin. Evidence for the different effectiveness of metformin subpopulations was provided using the mixture model. In the final PPD model, the inhibition effect was constant over a study duration in a patient subpopulation without secondary failure. In contrast, the inhibition effect decreased as a function of time after start of metformin treatment in a subpopulation with secondary failure. These results indicated that HbA1c improvements appeared to deteriorate over time in patients with secondary failure. In a PPD analysis of metformin, it was possible to assign patients with secondary failure using the mixture model.

元の言語英語
ページ(範囲)264-269
ページ数6
ジャーナルDrug metabolism and pharmacokinetics
33
発行部数6
DOI
出版物ステータス出版済み - 12 1 2018

Fingerprint

Metformin
Population
Therapeutics
Electronic Health Records
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

これを引用

Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models. / Tamaki, Yoko; Maema, Kunio; Kakara, Makoto; Fukae, Masato; Kinoshita, Ryoko; Kashihara, Yushi; Muraki, Shota; Hirota, Takeshi; Ieiri, Ichiro.

:: Drug metabolism and pharmacokinetics, 巻 33, 番号 6, 01.12.2018, p. 264-269.

研究成果: ジャーナルへの寄稿記事

Tamaki, Yoko ; Maema, Kunio ; Kakara, Makoto ; Fukae, Masato ; Kinoshita, Ryoko ; Kashihara, Yushi ; Muraki, Shota ; Hirota, Takeshi ; Ieiri, Ichiro. / Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models. :: Drug metabolism and pharmacokinetics. 2018 ; 巻 33, 番号 6. pp. 264-269.
@article{89ed348018594bb283014777d4e16b70,
title = "Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models",
abstract = "The objective of the present study was to develop a population pharmacodynamic (PPD) model to describe the glycated hemoglobin (HbA1c)-lowering effects of metformin in type 2 diabetes mellitus patients with and without secondary failure and to characterize changes in HbA1c levels in the two subpopulations using a mixture model. Information on patients was collected retrospectively from electronic medical records. In this study, the mixture model was used to characterize the bimodal effects of metformin. A PPD analysis was performed using NONMEM 7.3.0. A physiological indirect response model, based on 829 HbA1c levels of 69 patients, described the time course for the HbA1c-lowering effects of metformin. Evidence for the different effectiveness of metformin subpopulations was provided using the mixture model. In the final PPD model, the inhibition effect was constant over a study duration in a patient subpopulation without secondary failure. In contrast, the inhibition effect decreased as a function of time after start of metformin treatment in a subpopulation with secondary failure. These results indicated that HbA1c improvements appeared to deteriorate over time in patients with secondary failure. In a PPD analysis of metformin, it was possible to assign patients with secondary failure using the mixture model.",
author = "Yoko Tamaki and Kunio Maema and Makoto Kakara and Masato Fukae and Ryoko Kinoshita and Yushi Kashihara and Shota Muraki and Takeshi Hirota and Ichiro Ieiri",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.dmpk.2018.08.002",
language = "English",
volume = "33",
pages = "264--269",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "6",

}

TY - JOUR

T1 - Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models

AU - Tamaki, Yoko

AU - Maema, Kunio

AU - Kakara, Makoto

AU - Fukae, Masato

AU - Kinoshita, Ryoko

AU - Kashihara, Yushi

AU - Muraki, Shota

AU - Hirota, Takeshi

AU - Ieiri, Ichiro

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The objective of the present study was to develop a population pharmacodynamic (PPD) model to describe the glycated hemoglobin (HbA1c)-lowering effects of metformin in type 2 diabetes mellitus patients with and without secondary failure and to characterize changes in HbA1c levels in the two subpopulations using a mixture model. Information on patients was collected retrospectively from electronic medical records. In this study, the mixture model was used to characterize the bimodal effects of metformin. A PPD analysis was performed using NONMEM 7.3.0. A physiological indirect response model, based on 829 HbA1c levels of 69 patients, described the time course for the HbA1c-lowering effects of metformin. Evidence for the different effectiveness of metformin subpopulations was provided using the mixture model. In the final PPD model, the inhibition effect was constant over a study duration in a patient subpopulation without secondary failure. In contrast, the inhibition effect decreased as a function of time after start of metformin treatment in a subpopulation with secondary failure. These results indicated that HbA1c improvements appeared to deteriorate over time in patients with secondary failure. In a PPD analysis of metformin, it was possible to assign patients with secondary failure using the mixture model.

AB - The objective of the present study was to develop a population pharmacodynamic (PPD) model to describe the glycated hemoglobin (HbA1c)-lowering effects of metformin in type 2 diabetes mellitus patients with and without secondary failure and to characterize changes in HbA1c levels in the two subpopulations using a mixture model. Information on patients was collected retrospectively from electronic medical records. In this study, the mixture model was used to characterize the bimodal effects of metformin. A PPD analysis was performed using NONMEM 7.3.0. A physiological indirect response model, based on 829 HbA1c levels of 69 patients, described the time course for the HbA1c-lowering effects of metformin. Evidence for the different effectiveness of metformin subpopulations was provided using the mixture model. In the final PPD model, the inhibition effect was constant over a study duration in a patient subpopulation without secondary failure. In contrast, the inhibition effect decreased as a function of time after start of metformin treatment in a subpopulation with secondary failure. These results indicated that HbA1c improvements appeared to deteriorate over time in patients with secondary failure. In a PPD analysis of metformin, it was possible to assign patients with secondary failure using the mixture model.

UR - http://www.scopus.com/inward/record.url?scp=85055113767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055113767&partnerID=8YFLogxK

U2 - 10.1016/j.dmpk.2018.08.002

DO - 10.1016/j.dmpk.2018.08.002

M3 - Article

VL - 33

SP - 264

EP - 269

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 6

ER -